Evaluation of ammonia and lidocaine clearance, and galactose elimination capacity of xenoperfused pig livers using a pharmacokinetic analysis.

BACKGROUND We introduced the pharmacokinetic method into the functional evaluation of xenogeneic extracorporeal liver perfusion as an artificial liver assist device, and examined the influence of xenogeneic humoral injury on the metabolic function of xenoperfused pig livers. METHODS Isolated pig livers were perfused with fresh porcine blood (group 1; n=5) or fresh human blood (group 2; n=5) for 9 hr. Clearance (CL) of ammonia and lidocaine, and galactose elimination capacity (Vmax) were determined at three points during the perfusion using a one-compartment pharmacokinetic model. RESULTS Concentrations of ammonia and lidocaine decreased exponentially and those of galactose decreased linearly after a bolus injection in both groups. A one-compartment model provided satisfactory curve fittings for these test substances. No decreases of ammonia CL, lidocaine CL, or galactose Vmax were observed until 9 hr in either group. No differences were observed between the two groups with respect to these metabolic functions. In group 1, only slight interlobular edema was observed at 9 hr. In group 2, membrane attack complex was diffusely deposited at 3 hr and severe interlobular damage was histologically observed at 9 hr, although hepatocellular damage was minimal even at 9 hr. Alpha glutathione S-transferase and mitochondrial aspartate aminotransferase were comparable between the two groups. CONCLUSIONS Pharmacokinetic analysis allowed the evaluation of ammonia CL, lidocaine CL, and galactose Vmax of the perfused pig livers. Despite xenogeneic humoral injuries, the xenoperfused livers maintained these metabolic functions at the same levels as the alloperfused livers for 9 hr.

[1]  J. Villeneuve,et al.  Determinants of Drug Disposition in Patients with Cirrhosis , 2007, Hepatology.

[2]  H. Shinohara,et al.  The protective effects of prostaglandin E1 on sinusoidal endothelial cells in xenogeneic pig liver perfusion. , 1997, Journal of Surgical Research.

[3]  P. Olinga,et al.  Value of the in vitro or in vivo monoethylglycinexylidide test for predicting liver graft function. , 1997, Transplantation.

[4]  H. Shinohara,et al.  Successful long-term xenoperfusion of the pig liver: continuous administration of prostaglandin E1 and insulin. , 1997, Transplantation.

[5]  G. Budillon,et al.  Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. , 1996, Journal of hepatology.

[6]  G. Marchesini,et al.  The galactose elimination capacity test: a study of the technique based on the analysis of 868 measurements. , 1996, The American journal of gastroenterology.

[7]  J. Hoofnagle,et al.  Fulminant hepatic failure: Summary of a workshop , 1995, Hepatology.

[8]  G. Alexander,et al.  Serum alpha-glutathione S-transferase--a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. , 1994, Transplantation.

[9]  P. Parrilla,et al.  Blood ammonia levels as early indicator of allograft viability in human orthotopic liver transplantation. , 1994, The American journal of gastroenterology.

[10]  W. Meyers,et al.  Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. , 1994, The New England journal of medicine.

[11]  H. Jauregui,et al.  Mammalian hepatocytes as a foundation for treatment in human liver failure , 1991, Journal of cellular biochemistry.

[12]  M. Panteghini Aspartate aminotransferase isoenzymes. , 1990, Clinical biochemistry.

[13]  C. Gips,et al.  AMMONIA KINETICS IN 8 PATIENTS WITH LIVER-DISEASE AND IN DOGS , 1987 .

[14]  L. Ranek,et al.  Assessment of Prognosis in Fulminant Hepatic Failure , 1986, Seminars in liver disease.

[15]  N. Tygstrup,et al.  Michaelis-Menten kinetics of galactose elimination by the isolated perfused pig liver. , 1976, The American journal of physiology.

[16]  G. Abouna,et al.  Experience in the treatment of hepatic failure by intermittent liver hemoperfusions. , 1973, Surgery, gynecology & obstetrics.

[17]  B. Eiseman,et al.  Heterologous liver perfusion in treatment of hepatic failure. , 1965, Annals of surgery.

[18]  S. Nyberg,et al.  Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. , 1993, ASAIO journal (1992).

[19]  M. Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[20]  C. Wittekind,et al.  Monoethylglycinexylidide Formation Kinetics: A Novel Approach to Assessment of Liver Function , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[21]  S. Keiding,et al.  Hepatic galactose elimination kinetics in the intact pig. , 1982, Scandinavian journal of clinical and laboratory investigation.

[22]  R. Lutz,et al.  Physiological pharmacokinetics: an in vivo approach to membrane transport. , 1980, Pharmacology & therapeutics.